

Issued by JPAC: 11 January 2022

Implementation: To be determined by each Service

Change Notification UK National Blood Services No. 44 - 2021

Annex 5: Blood Components for Contingency Use

This change applies to the Guidelines for the Blood Transfusion Services in the United Kingdom 8th Edition 2013

Guidance notes for use when implementing components for contingency use.

This guidance has been produced in order to provide Blood Establishments with a checklist of items to be considered before implementing components for contingency use, or reactivation of components after they have been archived.

The findings may then inform any further validation work that is required prior to activation of a component.

Guidance

Before implementing or reactivating a component, the following should be considered:

- Any changes that individual Blood Establishments have since made to the way blood or blood components have been collected, including by whole blood or component donation. This must include blood bag material/plasticiser and anticoagulant etc.
- Any changes that individual Blood Establishments have since made to their manufacturing processes, as these may impact on component quality
- A review of any new scientific or clinical data in the context of the specification
- A review of the original validation data and output report, including any caveats or stipulations around use or application
- A review of the specification to ensure that the content remains current and accurate (this might also include a comparison with a similar or relevant component in Chapter 7)
- A review of any other, or new, specific clinical indications for use
- Approval from JPAC for use of the component in the context of the relevant situation (i.e. subject to a case by case review).

Sheila MacLennan

Dr Sheila MacLennan
Professional Director - Joint UKBTS Professional Advisory Committee
✉ sheila.maclennan@nhsbt.nhs.uk